指南与共识神经肿瘤

国际立体定向放射外科协会复发高级别胶质瘤放射外科实践指南

International Stereotactic Radiosurgery Society (ISRS) practice guidelines for radiosurgery in recurrent high-grade glioma.
指南 / 共识 · Neuro Oncol · 2026-01-01

主要结论:单次16 Gy或3-5次24-25 Gy的局部再照射安全且似乎有效;HFSRS神经毒性低于SRS(4% vs 7%,P=0.001);累积EQD2>120-130 Gy与放射性坏死风险显著相关(P=0.003)。

要点

  • 复发高级别胶质瘤挽救性SRS推荐单次16 Gy,HFSRS推荐3-5次24-25 Gy。
  • HFSRS神经毒性发生率低于SRS(4% vs 7%,P=0.001)。
  • 累积EQD2>120-130 Gy显著增加放射性坏死风险(P=0.003)。

核心结论

  • 单次16 Gy或3-5次24-25 Gy的局部再照射对复发高级别胶质瘤安全且似乎有效。
  • 鉴于前瞻性数据有限,无法得出确定性结论。

研究设计与样本

  • 国际立体定向放射外科协会(ISRS)依据PRISMA指南进行文献综述与荟萃分析,并按DELPHI法制定推荐。

主要发现

  • 75%患者接受SRS,中位总剂量16 Gy;25%接受HFSRS,中位总剂量25 Gy、5次。
  • 再照射后中位总生存期为10.2个月。
  • HFSRS的汇总神经毒性发生率低于SRS(4% vs 7%,P=0.001)。
  • 累积EQD2大于120-130 Gy与放射性坏死风险显著增加相关(P=0.003)。

关键数值与推荐

  • SRS定义为单次聚焦放疗,HFSRS定义为2-5次聚焦放疗。
  • 推荐单次16 Gy或3-5次24-25 Gy的局部再照射用于复发高级别胶质瘤。
  • 累积EQD2超过120-130 Gy时需警惕放射性坏死风险。

临床怎么用

  • 对选择性复发高级别胶质瘤患者,可考虑单次16 Gy SRS或3-5次24-25 Gy HFSRS作为挽救治疗。
  • 优先选择HFSRS可能降低神经毒性风险;需关注累积EQD2不超过120-130 Gy以减少放射性坏死。

局限性

  • 前瞻性数据有限,无法得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence invariably occurs in patients with high-grade glioma (HGG) despite maximal definitive therapy. Currently, there is no standard-of-care salvage treatment approach and re-irradiation is considered an option for select patients. Various radiotherapy fractionation schedules have been investigated, including the use of stereotactic radiosurgery (SRS). The aim of this study was to provide clinical practice recommendations on behalf of the International Stereotactic Radiosurgery Society (ISRS) specific to salvage SRS for recurrent-HGG. We define SRS as focal radiation in a single fraction and hypofractionated radiosurgery (HFSRS) as focal radiation delivered over 2-5 fractions. METHODS: A literature review and meta-analysis were performed according to PRISMA guidelines. Recommendations were formulated according to DELPHI methodology. RESULTS: Sixty-two studies met the eligibility criteria for analyses, resulting in 2640 recurrent HGG patients. Stereotactic radiosurgery to a median total dose of 16 Gy was performed in 75% of patients, and HFSRS to the remaining 25% with a median total dose and number of fractions of 25 Gy and 5 fractions, respectively. The median overall survival from re-irradiation was 10.2 months. The pooled neurological toxicity rates were lower with HFSRS compared to SRS (4% vs. 7%, P = 0.001). A cumulative EQD2 greater than 120-130 Gy was significantly associated with a greater risk of radiation necrosis (P = 0.003). CONCLUSIONS: Focal re-irradiation with 16 Gy in single fraction or 24-25 Gy in 3-5 fractions, is safe and appears to be effective for recurrent-HGG. We also present clinical practice recommendations on behalf of the ISRS. Given the limited prospective data, no definitive conclusions can be drawn.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Pinzi V, Kotecha R, Sahgal A, et al. International Stereotactic Radiosurgery Society (ISRS) practice guidelines for radiosurgery in recurrent high-grade glioma. Neuro Oncol. 2026. PMID: 41143546. doi:10.1093/neuonc/noaf247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。